Oric Pharmaceuticals (ORIC) CFO receives option and RSU awards

Rhea-AI Filing Summary

Oric Pharmaceuticals Chief Financial Officer Dominic Piscitelli reported new equity awards. On January 2, 2026, he received a stock option covering 206,500 shares of Oric common stock with an exercise price of $8.17 per share. According to the vesting terms, 25% of these option shares vest on January 2, 2027, and the remaining shares vest in equal monthly installments over the following 36 months.

He was also granted 34,500 restricted stock units (RSUs), each representing a right to receive one share of Oric common stock. One-third of these RSUs vests on each of December 15, 2026, December 15, 2027, and December 15, 2028. Both the option and RSUs are reported as directly owned and were acquired as part of his compensation.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Piscitelli Dominic

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	206,500	$0.00	--
Grant/Award	Restricted Stock Unit	34,500	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 206,500 shares (Direct); Restricted Stock Unit — 34,500 shares (Direct)

Footnotes (1)

1. 25% of the shares subject to the option shall vest on January 2, 2027, and 1/36th of the remaining shares subject to the option shall vest each month thereafter. Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. Common Stock. 1/3rd of the RSUs subject to the award shall vest on each of December 15, 2026, December 15, 2027 and December 15, 2028.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Piscitelli Dominic

(Last) (First) (Middle)

C/O ORIC PHARMACEUTICALS, INC.

240 E. GRAND AVE., 2ND FLOOR

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Oric Pharmaceuticals, Inc. [ ORIC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$8.17	01/02/2026		A		206,500		(1)	01/01/2036	Common Stock	206,500	$0	206,500	D
Restricted Stock Unit	(2)	01/02/2026		A		34,500		(3)	(3)	Common Stock	34,500	$0	34,500	D

Explanation of Responses:

1. 25% of the shares subject to the option shall vest on January 2, 2027, and 1/36th of the remaining shares subject to the option shall vest each month thereafter.

2. Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. Common Stock.

3. 1/3rd of the RSUs subject to the award shall vest on each of December 15, 2026, December 15, 2027 and December 15, 2028.

	/s/ Christian Kuhlen, attorney-in-fact	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did ORIC report in this Form 4 filing?

The filing reports that Chief Financial Officer Dominic Piscitelli acquired a stock option for 206,500 shares at $8.17 per share and 34,500 RSUs on January 2, 2026, as part of his compensation.

How many stock options did ORIC CFO Dominic Piscitelli receive and at what price?

Dominic Piscitelli received a stock option (right to buy) for 206,500 shares of Oric Pharmaceuticals common stock with an exercise price of $8.17 per share.

What is the vesting schedule for the ORIC CFO stock options granted on January 2, 2026?

For the stock option, 25% of the 206,500 shares vest on January 2, 2027. The remaining shares vest in 1/36th increments each month thereafter until fully vested.

How many restricted stock units did the ORIC CFO receive and what do they represent?

He received 34,500 restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Oric Pharmaceuticals, Inc. common stock.

What is the vesting schedule for the ORIC CFO restricted stock units?

The 34,500 RSUs vest in three equal installments: 1/3 on each of December 15, 2026, December 15, 2027, and December 15, 2028.

Are the ORIC CFO equity awards held directly or indirectly?

Both the 206,500 stock options and the 34,500 RSUs are reported as directly owned by Dominic Piscitelli, with no indirect ownership entity disclosed.